GALT — GALECTIN THERAPEUTICS INC
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2016-01-04.
Performance
Technicals
Others in Healthcare
Measured signals that fired on GALT
| date | signal | measured base rate |
|---|---|---|
| 2026-06-29 | Volume shock without a price move price | -1.33% over 21 days · t = -4.53 · n = 16,432 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-07-31 | Uihlein Richard E Director | Option exercise | 31.8M | 3.00 | 95.5M |
| 2026-07-31 | Uihlein Richard E Director | Option exercise | 2.6M | 4.05 | 10.3M |
| 2026-07-14 | Jamil Khurram Chief Medical Officer | Open-market sale 10b5-1 plan | 16.2K | 5.13 | 83.3K |
| 2026-07-14 | Jamil Khurram Chief Medical Officer | Option exercise 10b5-1 plan | 16.2K | 3.04 | 49.4K |
| 2026-06-29 | Jamil Khurram Chief Medical Officer | Open-market sale 10b5-1 plan | 47.5K | 5.04 | 239.2K |
| 2026-06-29 | Jamil Khurram Chief Medical Officer | Option exercise 10b5-1 plan | 47.5K | 2.50 | 118.7K |
| 2026-06-29 | Shlevin Harold H. Director | Open-market sale 10b5-1 plan | 22.3K | 5.04 | 112.2K |
| 2026-06-29 | Shlevin Harold H. Director | Option exercise 10b5-1 plan | 22.3K | 1.23 | 27.4K |
| 2026-06-26 | Shlevin Harold H. Director | Open-market sale 10b5-1 plan | 7.7K | 5.00 | 38.7K |
| 2026-06-26 | Jamil Khurram Chief Medical Officer | Open-market sale 10b5-1 plan | 2.5K | 5.00 | 12.7K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | 5.5M | 2.0M |
| MARSHALL WACE, LLP | 3.4M | 1.2M |
| OSAIC HOLDINGS, INC. | 3.1M | 1.1M |
| BlackRock, Inc. | 2.2M | 799.2K |
| MILLENNIUM MANAGEMENT LLC | 2.2M | 798.4K |
| Wealthspire Advisors, LLC | 2.0M | 721.8K |
| GEODE CAPITAL MANAGEMENT, LLC | 1.7M | 612.8K |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1.6M | 555.7K |
| TWO SIGMA INVESTMENTS, LP | 1.3M | 467.1K |
| COMMONWEALTH EQUITY SERVICES, LLC | 1.0M | 367.1K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| 8-K | 2026-08-14 | 2026-08-14 | on EDGAR ↗ |
| 10-Q | 2026-08-14 | 2026-06-30 | on EDGAR ↗ |
| SCHEDULE 13D/A | 2026-08-04 | — | on EDGAR ↗ |
| 4 | 2026-08-04 | 2026-07-31 | on EDGAR ↗ |
| 8-K | 2026-08-04 | 2026-07-31 | on EDGAR ↗ |
| 4 | 2026-07-16 | 2026-07-14 | on EDGAR ↗ |
| 4 | 2026-06-30 | 2026-06-26 | on EDGAR ↗ |
| 4 | 2026-06-30 | 2026-06-26 | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Galectin Therapeutics reports Q2 results · 2026-08-14
- Galectin Therapeutics Inc (GALT) filed form 8-K · 2026-08-14 · SEC EDGAR
- GALECTIN THERAPEUTICS INC (GALT) filed form 8-K · 2026-08-14 · SEC EDGAR
- GALECTIN THERAPEUTICS INC (GALT) filed form 10-Q · 2026-08-14 · SEC EDGAR
Ask the AI about GALT
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →